Maintenance Therapy for Small-cell Lung Cancer
NCT03769935
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
90
Enrollment
OTHER
Sponsor class
Conditions
Progression Free Survival
Interventions
DRUG:
cis Platinum, etoposide, S1
Sponsor
Qingdao Central Hospital